Floatz logo

Zilovertamab Vedotin

Richter Transformation Lymphoma

Merck Sharp & Dohme LLCantibody_drug_conjugatePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

56 Active assets in the Richter Transformation Lymphoma cohort.

Asset / SponsorPhaseRating
Obinutuzumab
Christine Ryan
Phase 2BB
Ibrutinib
City of Hope Medical Center
Phase 2BB
Venetoclax
Northwestern University
Phase 2BB
Pirtobrutinib
SWOG Cancer Research Network
Phase 3BB
Cyclophosphamide
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Zilovertamab Vedotin is also rated in:

diffuse large B-cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaDormant
B
Indicative ·
57 / 100
View asset →
Burkitt lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →